Hangzhou Yivensai Biotechnology

Evive Biotechnology, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company focused on developing novel biological therapies for oncology, inflammatory, and regenerative diseases. The company's lead product, Ryzneuta (efbemalenograstim alfa), is a long-acting G-CSF fusion protein that received FDA and NMPA approval in 2023 for the treatment of chemotherapy-induced neutropenia. Evive utilizes its proprietary Di-Kine platform to engineer cytokine-based therapies, including its clinical-stage candidate F-652, a recombinant human IL-22. The company operates significant R&D and manufacturing facilities in Hangzhou and Shanghai, China, supporting its global commercialization and development efforts.